View Financial HealthThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsForward Pharma 配当と自社株買い配当金 基準チェック /06Forward Pharma配当金を支払った記録がありません。主要情報n/a配当利回り-0.007%バイバック利回り総株主利回り-0.007%将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesお知らせ • May 19Forward Pharma A/S, Annual General Meeting, Jun 08, 2023Forward Pharma A/S, Annual General Meeting, Jun 08, 2023, at 14:00 Central European Standard Time. Location: company's premises, Østergade 24A, 1 st floor, Copenhagen K Denmark Agenda: To consider the board of director's report on the company's activities in the past financial year; to consider adoption of the audited annual report 2022; to consider the result for the accounting year 2022 according to the adopted annual report be carried forward by transfer to the next financial year; and to consider other matters.お知らせ • Dec 29Forward Pharma A/S(OTCPK:FWPA.Y) dropped from NASDAQ Composite IndexForward Pharma A/S will be removed from NASDAQ Composite Index.お知らせ • Dec 21Forward Pharma Announces Expected Delisting of ADS from the Nasdaq Capital MarketForward Pharma A/S (“we” or “Forward”) announced that on December 16, 2022 it received written notice from The Nasdaq Stock Market LLC (“Nasdaq”) notifying us that Nasdaq believes that Forward is a "public shell" pursuant to Listing Rule 5101, and that the continued listing of its securities is no longer warranted. We will not appeal this determination. Therefore, we expect the trading of our American Depositary Shares on The Nasdaq Capital Market to be suspended at the opening of business on December 28, 2022, and that Nasdaq will file a Form 25-NSE with the U.S. Securities and Exchange Commission (the “SEC”), which will remove Forward’s securities from listing and registration on The Nasdaq Stock Market. Additionally, we intend to file with the SEC a Form 15 requesting the suspension of Forward’s reporting obligations.Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 2 highly experienced directors. 2 independent directors (3 non-independent directors). Independent Non-Executive Director Duncan Moore was the last independent director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.お知らせ • May 06Forward Pharma A/S, Annual General Meeting, May 20, 2022Forward Pharma A/S, Annual General Meeting, May 20, 2022, at 14:00 Central European Standard Time. Location: at the company premises, Østergade 24A, 1st floor, 1100 Copenhagen Denmark Agenda: To consider the report on the company's activities in the past financial year; to consider the presentation and adoption of the audited annual report; to consider the distribution of profit or covering of loss according to the adopted annual report; to discharge of the board of directors and the management board; to consider the election of members to the board of directors; to consider the appointment of auditor; and to consider the other matters.Board Change • Apr 28Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 2 highly experienced directors. 2 independent directors (3 non-independent directors). Independent Non-Executive Director Duncan Moore was the last independent director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.お知らせ • Jan 13Forward Pharma A/S Announces Rescheduling of the EP2801355 Appeal Hearing to September 6, 2021 due to COVID-19 RestrictionsForward Pharma A/S announced that due to ongoing precautionary measures against the spread of the novel coronavirus (“COVID-19”), the Technical Board of Appeal (the “TBA”) of the European Patent Office (the “EPO”) again has rescheduled the oral hearing of the appeal against the decision of the Opposition Division that revoked the EP2801355 patent (the “’355 Patent”). The new hearing date is set for September 6, 2021.決済の安定と成長配当データの取得安定した配当: 1FPBの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: 1FPBの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場Forward Pharma 配当利回り対市場1FPB 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (1FPB)n/a市場下位25% (DE)1.5%市場トップ25% (DE)4.5%業界平均 (Biotechs)2.2%アナリスト予想 (1FPB) (最長3年)n/a注目すべき配当: 1FPBは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: 1FPBは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: 1FPBの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: 1FPBが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YDE 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2023/04/02 12:27終値2023/01/04 00:00収益2022/06/30年間収益2021/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Forward Pharma A/S これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。4 アナリスト機関Jason ButlerCitizens JMP Securities, LLCThomas WeiJefferies LLCJason Matthew GerberryLeerink Partners LLC1 その他のアナリストを表示
お知らせ • May 19Forward Pharma A/S, Annual General Meeting, Jun 08, 2023Forward Pharma A/S, Annual General Meeting, Jun 08, 2023, at 14:00 Central European Standard Time. Location: company's premises, Østergade 24A, 1 st floor, Copenhagen K Denmark Agenda: To consider the board of director's report on the company's activities in the past financial year; to consider adoption of the audited annual report 2022; to consider the result for the accounting year 2022 according to the adopted annual report be carried forward by transfer to the next financial year; and to consider other matters.
お知らせ • Dec 29Forward Pharma A/S(OTCPK:FWPA.Y) dropped from NASDAQ Composite IndexForward Pharma A/S will be removed from NASDAQ Composite Index.
お知らせ • Dec 21Forward Pharma Announces Expected Delisting of ADS from the Nasdaq Capital MarketForward Pharma A/S (“we” or “Forward”) announced that on December 16, 2022 it received written notice from The Nasdaq Stock Market LLC (“Nasdaq”) notifying us that Nasdaq believes that Forward is a "public shell" pursuant to Listing Rule 5101, and that the continued listing of its securities is no longer warranted. We will not appeal this determination. Therefore, we expect the trading of our American Depositary Shares on The Nasdaq Capital Market to be suspended at the opening of business on December 28, 2022, and that Nasdaq will file a Form 25-NSE with the U.S. Securities and Exchange Commission (the “SEC”), which will remove Forward’s securities from listing and registration on The Nasdaq Stock Market. Additionally, we intend to file with the SEC a Form 15 requesting the suspension of Forward’s reporting obligations.
Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 2 highly experienced directors. 2 independent directors (3 non-independent directors). Independent Non-Executive Director Duncan Moore was the last independent director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
お知らせ • May 06Forward Pharma A/S, Annual General Meeting, May 20, 2022Forward Pharma A/S, Annual General Meeting, May 20, 2022, at 14:00 Central European Standard Time. Location: at the company premises, Østergade 24A, 1st floor, 1100 Copenhagen Denmark Agenda: To consider the report on the company's activities in the past financial year; to consider the presentation and adoption of the audited annual report; to consider the distribution of profit or covering of loss according to the adopted annual report; to discharge of the board of directors and the management board; to consider the election of members to the board of directors; to consider the appointment of auditor; and to consider the other matters.
Board Change • Apr 28Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 2 highly experienced directors. 2 independent directors (3 non-independent directors). Independent Non-Executive Director Duncan Moore was the last independent director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
お知らせ • Jan 13Forward Pharma A/S Announces Rescheduling of the EP2801355 Appeal Hearing to September 6, 2021 due to COVID-19 RestrictionsForward Pharma A/S announced that due to ongoing precautionary measures against the spread of the novel coronavirus (“COVID-19”), the Technical Board of Appeal (the “TBA”) of the European Patent Office (the “EPO”) again has rescheduled the oral hearing of the appeal against the decision of the Opposition Division that revoked the EP2801355 patent (the “’355 Patent”). The new hearing date is set for September 6, 2021.